| New Drug Thwarts
a Chronic Leukemia
By deactivating a
rogue enzyme, a drug called STI-571 dramatically improves the health of
people with chronic myelogenous leukemia, a deadly disease.
References:
Druker, B.J., et
al. 1999. Clinical efficacy and safety of an Abl specific tyrosine
kinase inhibitor as targeted therapy for chronic myelogenous leukemia
. Meeting of the American Society of Hematology. December. New
Orleans.
Further Readings:
1960. Abnormal
leukemia cells. Science News Letter 78(Nov. 26):341.
Cline, M.J. 1994.
The molecular basis of leukemia. New England Journal of Medicine
330(Feb. 3):328.
Nowell, P.C., and
D.A. Hungerford. 1960. Chromosome studies on normal and leukemic human
leukocytes. Journal of the National Cancer Institute 25:85.
Rowley, J.D. 1973.
A new consistent chromosomal abnormality in chronic myelogenous leukemia
identified by quinacrine fluorescence and Giemsa staining. Nature
243:290.
Sources:
Brian J. Druker
Oregon Health Sciences University
Departments of Hematology and Medical Oncology
L-592
Portland, OR 97201
John Groffen
Children’s Hospital
4650 Sunset Boulevard
Mailstop Code 54
Los Angeles, CA 90027
From Science
News, Vol. 156, No. 24, December 11, 1999, p. 372. Copyright ©
1999, Science Service. |